Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. Reply

Stephen M. Ansell; John Radford; David J. Straus

doi:10.1056/NEJMc2211125

Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. Reply

Stephen M. Ansell, John Radford, David J. Straus

Hematology

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1527-1528
Number of pages	2
Journal	The New England journal of medicine
Volume	387
Issue number	16
DOIs	https://doi.org/10.1056/NEJMc2211125
State	Published - Oct 20 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJMc2211125

Cite this

@article{0f1c91d85eb8411394856e5478ccffa4,

title = "Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. Reply",

author = "Ansell, {Stephen M.} and John Radford and Straus, {David J.}",

year = "2022",

month = oct,

day = "20",

doi = "10.1056/NEJMc2211125",

language = "English (US)",

volume = "387",

pages = "1527--1528",

journal = "The New England journal of medicine",

issn = "1533-4406",

publisher = "Massachussetts Medical Society",

number = "16",

}

TY - JOUR

T1 - Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. Reply

AU - Ansell, Stephen M.

AU - Radford, John

AU - Straus, David J.

PY - 2022/10/20

Y1 - 2022/10/20

UR - http://www.scopus.com/inward/record.url?scp=85140414954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140414954&partnerID=8YFLogxK

U2 - 10.1056/NEJMc2211125

DO - 10.1056/NEJMc2211125

M3 - Letter

C2 - 36260801

AN - SCOPUS:85140414954

SN - 1533-4406

VL - 387

SP - 1527

EP - 1528

JO - The New England journal of medicine

JF - The New England journal of medicine

IS - 16

ER -

Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this